1 Min Read
Oct 5 (Reuters) - Cymabay Therapeutics :
* Initiates its next phase 2 study of MBX-8025 in primary biliary cholangitis
* Initiation of phase 2 study is expected by year end 2016. Source text for Eikon: Further company coverage:
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2017 Reuters. All Rights Reserved.